Rational choice of cholinesterase inhibitor for the treatment of Alzheimer's disease in Canada: a comparative economic analysis

BACKGROUND: Cholinesterase inhibitors, such as galantamine, donepezil and rivastigmine are approved for symptomatic treatment of Alzheimer's Disease (AD) in Canada. In making choices amongst these drugs, one should consider their clinical merits and their economic implications. METHODS: Each dr...

Descripción completa

Detalles Bibliográficos
Autores principales: Caro, Jaime, Getsios, Denis, Migliaccio-Walle, Kristen, Ishak, Jack, El-Hadi, Wissam
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2003
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC317304/
https://www.ncbi.nlm.nih.gov/pubmed/14675494
http://dx.doi.org/10.1186/1471-2318-3-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC317304/
https://www.ncbi.nlm.nih.gov/pubmed/14675494
http://dx.doi.org/10.1186/1471-2318-3-6

Ejemplares similares